<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586883</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A00731-48</org_study_id>
    <nct_id>NCT02586883</nct_id>
  </id_info>
  <brief_title>Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi</brief_title>
  <acronym>EPITRANS</acronym>
  <official_title>Study of the Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify the abnormalities of bronchial trans-epithelial&#xD;
      transport of chloride, sodium and bicarbonate in patients with idiopathic dilations of the&#xD;
      bronchi.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dilations of the bronchi happens for one child over 3000. The extended forms may progress to&#xD;
      respiratory failure. More than one case over two remains of undetermined cause. If the&#xD;
      prototype is the cystic fibrosis, other abnormalities of ionic transport may be the cause of&#xD;
      a failure of mucociliary clearance and enhance the idiopathic dilations of the bronchi.&#xD;
&#xD;
      The purpose of this study is to identify the abnormalities of bronchial trans-epithelial&#xD;
      transport of chloride, sodium and bicarbonate in patients with idiopathic dilations of the&#xD;
      bronchi, in comparison to two others groups of patients (without abnormality of ionic&#xD;
      transport/with typical cystic fibrosis).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2016</start_date>
  <completion_date type="Actual">November 23, 2020</completion_date>
  <primary_completion_date type="Actual">November 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to isoproterenol in solution without chloride ions during bronchial potential difference test (ΔIsoprotérénol / bronchial).</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Difference between groups for Level of repolarisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to amiloride during bronchial potential difference test</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-epithelial transport measured in vivo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trans-epithelial ionic transport in the nasal epithelium (nasal DDP)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-epithelial transport measured in vivo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trans-epithelial ionic transport of sweat epithelium (sweat test)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-epithelial transport measured in vivo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal current short circuit</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Epithelial Sodium Channel (ENaC) inhibitors</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) (inh-172)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of Calcium (Ca)-dependent Chloride (Cl-) ion channels</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of Solute Carrier family 26, member 9 (SLC26A9)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to inhibitors of potassium (K+ ) secretion basolateral</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bicarbonate (HCO3- ) secretion in response to forskolin</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Idiopathic Dilation of the Bronchi</condition>
  <arm_group>
    <arm_group_label>Patients with multiple bronchi dilations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients without transport abnormality</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with typical cystic fibrosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bronchial ddp test</intervention_name>
    <description>bronchial ddp test during endoscopy, nasal smear, bronchial smear</description>
    <arm_group_label>Control patients without transport abnormality</arm_group_label>
    <arm_group_label>Patients with multiple bronchi dilations</arm_group_label>
    <arm_group_label>Patients with typical cystic fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Common criteria for all patients&#xD;
&#xD;
          -  Age between 2 and 20 years.&#xD;
&#xD;
          -  Patient weighing more than 12kg&#xD;
&#xD;
          -  Patients with a scheduled bronchoscopy under clinical monitoring (assessment of&#xD;
             bronchial involvement, local samples for bacteriological and histological examination)&#xD;
&#xD;
          -  Signature of consent by the patient or by the / the holder (s) of parental authority&#xD;
             and the investigator&#xD;
&#xD;
          -  Patient affiliated to a social security scheme or entitled&#xD;
&#xD;
          -  Patient with contraception (for woman of childbearing age) Specific criteria for&#xD;
             idiopathic bronchiectasis patients Patient with idiopathic bronchiectasis in at least&#xD;
             two lobes, diagnosis made after extensive screening of known acquired or congenital&#xD;
             causes&#xD;
&#xD;
        Specific criteria for &quot;control&quot; patients without abnormal ion transport&#xD;
&#xD;
          -  Patient Not having bronchiectasis s or any supposed alteration in transepithelial ion&#xD;
             transport&#xD;
&#xD;
          -  Patients with fiberoptic bronchoscopy performed for one of the following indications:&#xD;
&#xD;
          -  Pulmonary malformations&#xD;
&#xD;
          -  Laryngeal, tracheal, bronchomalacia&#xD;
&#xD;
          -  Airway compression&#xD;
&#xD;
          -  Interstitial pathology&#xD;
&#xD;
          -  Suspicion of foreign body&#xD;
&#xD;
          -  Suspected tuberculosis Specific criteria for patients with a typical form of cystic f&#xD;
             ibrosis (CF) Patient carrying 2 causing mutations in the CFTR gene (according to CFTR2&#xD;
             database; http://www.cftr2.org/mutations_history.php) and sweat test&gt; 60&#xD;
             milliequivalent per liter (mEq/L).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Common criteria for all patients&#xD;
&#xD;
          -  Smoking passive or active&#xD;
&#xD;
          -  Not essential bronchial endoscopy in the clinical follow&#xD;
&#xD;
          -  Extension of bronchoscopy time attributed to the difference in potential bronchial&#xD;
             incompatible with the patient's general status&#xD;
&#xD;
          -  Patient pregnant or breast feeding&#xD;
&#xD;
          -  Hypersensitivity or cons known contraindications to health products for measurement of&#xD;
             DDP (isoproterenol, Amiloride, ATP)&#xD;
&#xD;
        Specific criteria for idiopathic DDB patients&#xD;
&#xD;
        Presence of other congenital or acquired etiologies of DDB:&#xD;
&#xD;
          -  Typical or atypical cystic fibrosis,&#xD;
&#xD;
          -  Immunodeficiency,&#xD;
&#xD;
          -  Primary ciliary dyskinesia,&#xD;
&#xD;
          -  Abnormal bronchial wall structure (Williams-Campbell syndrome, Mounier-Kuhn,&#xD;
             Ehlers-Danlos syndrome, Marfan's disease)&#xD;
&#xD;
          -  Infectious DDBs post&#xD;
&#xD;
          -  Extrinsic or endobronchial obstruction (foreign body, malformation, middle lobe&#xD;
             syndrome)&#xD;
&#xD;
          -  Chronic inhalation (GERD, swallowing disorders, gastroesophageal tracheal fistula)&#xD;
&#xD;
          -  Allergic bronchopulmonary aspergillosis,&#xD;
&#xD;
          -  System disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Necker-Enfants Malades Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dilation of the Bronchi</keyword>
  <keyword>Bronchial potential difference</keyword>
  <keyword>Dilation of the Bronchi (DDB)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

